SGLT2 inhibitors can interact with oxidative stress, inflammation and other factors as exemplified by SGLT2 inhibitors’ influence on the pathophysiology of diabetic cardiomyopathy. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.